An Initiative of AVAC

Uganda

A snapshot of PrEP scale-up, registration and resources for Uganda.

  • 21,000-22,000
    Estimated Number of Current PrEP Users

    Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

  • 90,000
    PEPFAR PrEP Target in COP 2020

    Targets are set by PEPFAR country teams on an annual basis. Targets do not indicate funding is available for PrEP.

Data Updated: April 3, 2020

Drug Registration Status

  • Gilead's Truvada (TDF/FTC) registration
    Under review
  • Generic versions of TDF/FTC for prevention
    Approved

Types of Delivery Projects

  • Clinical trial
  • Demonstration projects, which road-test the use of new options in real-world settings—not in a trial site. They have a formal evaluation component that is designed to address specific elements of introduction such as infrastructure needs and ways individuals can integrate it into daily activities.
  • Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program.
  • National level — PrEP availability in government clinics.
  • Product introduction and support projects

Research, Demonstration and Implementation Projects

Policy Framework

Funding

  • The Bill & Melinda Gates Foundation
  • IMPAACT Network
  • Microbicide Trials Network (MTN)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)
  • National Institute of Mental Health (NIMH)
  • National Institute of Child Health and Human Development (NICHD)
  • Nike Foundation
  • International Partnership for Microbicides (IPM)
  • PEPFAR
  • Ugand Ministry of Health
  • United States Agency for International Development (USAID)

Eligibility Criteria

PrEP provides an effective additional biomedical prevention option for HIV-negative people at substantial risk of acquiring HIV infection. These include people who:

  • Have multiple sexual partners
  • Engage in transactional sex including sex workers
  • Use or abuse injectable drugs and alcohol
  • Have had more than one episode of an STI within the last twelve months
  • Are part of a discordant couple, especially if the HIV-positive partner is not on ART or has been on ART for less than six months
  • Are recurrent users of PEP (three consecutive cycles of PEP)
  • Engage in anal sex
  • Are members of key populations who are unable or unwilling to achieve consistent use of condoms

These risk factors are likely to be more prevalent in populations such as sex workers, fisher folk, long-distance truck drivers, men who have sex with men (MSM), uniformed forces and adolescents and young women engaged in transactional sex.

Resources for Uganda